Potent, long-acting, orally active M3 antagonist selected for clinical development at Banyu Dec. 15, 2000
TRK-851: clinical trials under way for selective DOP antagonist with antitussive activity Dec. 15, 2000
Kowa identifies aorta-selective ACAT inhibitor acting directly on atherosclerotic process Dec. 14, 2000
RSS